{
    "nct_id": "NCT05753501",
    "official_title": "First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies",
    "inclusion_criteria": "* For Dose Escalation (Part 1) only: Participants with documented diagnosis for one of the following 3L+ B-cell malignancies, from one of the following WHO-defined histologies (Swerdlow et al 2016):\n\n  * Chronic lymphocytic leukemia (CLL)\n  * Small lymphocytic lymphoma (SLL)\n  * Chimeric antigen receptor T-cells (CAR-T)/hematopoietic cell transplant (HCT) relapsed/refractory (R/R) or ineligible diffuse large b-cell lymphoma (DLBCL) from the following histologies: DLBCL not otherwise specified (NOS) (germinal center B cell [GCB] and non-GCB DLBCL), T-cell/histiocyte-rich large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS.\n  * Mantle cell lymphoma (MCL)\n  * Follicular lymphoma [FL] (grades 1-3b)\n  * Marginal zone lymphoma [MZL] (splenic, extranodal, and nodal)\n  * WaldenstrÃ¶m macroglobulinemia (WM)\n  * Transformed indolent non-Hodgkin's lymphoma (iNHL)\n* For Dose Expansion (Part 2) only: Participants with documented diagnosis of CLL who are 3L+ including those with Bruton's tyrosine kinase (BTK) mutations or CAR-T/HCT R/R or ineligible non-GCB DLBCL who are 3L+ with histology based on criteria established by the World Health Organization (WHO).\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2. For EU only: Participant has an ECOG PS of 0 or 1.\n* Participant has a life expectancy >= 12 weeks.\n* Prior Bruton's tyrosine kinase inhibitor (BTKi) is allowed.\n* Adequate hematologic, renal, and hepatic function per the protocol.\n* Participants with prior central nervous system (CNS) disease that have been effectively treated may be eligible.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previously treated with a Bruton's tyrosine kinase (BTK) degrader.\n* Known active CNS disease, or primary CNS lymphoma.\n* Uncontrolled active systemic infection, or active cytomegalovirus infection, known history of human immunodeficiency virus (HIV), active hepatitis B or C infection or less than 12 weeks since achieving undetectable viral load in cases of prior active hepatitis C.",
    "miscellaneous_criteria": ""
}